Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, which has been discontinued following a company reorganization [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that Intellia's management provided investors with optimistic timelines for the NTLA-3001 study, claiming the first patient would be dosed in the second half of 2024. However, they failed to disclose that demand for viral-based editing was declining as non-viral methods gained preference in the scientific community [1]. - The truth emerged on January 9, 2025, when Intellia announced the halting of all NTLA-3001 research and a 27% workforce reduction, indicating a shift in focus to other pharmaceutical developments [1]. Stock Price Impact - Following the announcement of the discontinuation of NTLA-3001, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to $10.20 per share on January 10, 2025, reflecting a significant loss in market value [1]. Next Steps for Shareholders - Shareholders who purchased NTLA shares during the specified class period are encouraged to register for the class action by April 14, 2025, to potentially become lead plaintiffs and receive updates on the case [2].

Core Viewpoint - A class action has been filed against Intellia Therapeutics, Inc. for allegedly misleading investors regarding the viability of its drug candidate NTLA-3001, which is intended for treating alpha-1 antitrypsin deficiency-associated lung disease [1][2]. Allegations - The complaint claims that during the class period, Intellia provided investors with optimistic information about its Phase 1/2 study for NTLA-3001, including expectations to dose the first patient in the second half of 2024 [2]. - It is alleged that Intellia failed to disclose that demand for viral-based editing was declining as non-viral delivery methods gained traction due to their cost-effectiveness and efficiency, making NTLA-3001 an inefficient program for the company [2]. Revelation of Truth - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and studies, and disclosed a workforce reduction of 27% in 2025, leading to a 15% decline in the company's stock price [3]. Next Steps for Shareholders - Shareholders may be eligible to participate in the class action and can contact Robbins LLP if they wish to serve as lead plaintiff, although participation is not required for recovery [4]. About Robbins LLP - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 30, 2024, and January 8, 2025 [1] Group 1: Lawsuit Details - The lawsuit aims to recover losses for Intellia investors who were impacted by the company's failure to disclose critical information regarding its Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency-associated lung disease [2] - Defendants allegedly misled investors by expressing confidence in the study's timeline, stating that the first patient would be dosed in the second half of 2024, while failing to reveal a significant decline in demand for viral-based editing methods [2] - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27%, which led to a significant drop in the company's stock price from $12.02 to $10.20 per share [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request to be appointed as lead plaintiff in the lawsuit [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the progress and viability of its NTLA-3001 program for treating alpha-1 antitrypsin deficiency-associated lung disease, which has now been discontinued [1][2]. Summary by Relevant Sections Allegations - The lawsuit claims that Intellia's management provided investors with optimistic timelines for the NTLA-3001 study, specifically stating that the first patient would be dosed in the second half of 2024 [1]. - It is alleged that the company failed to disclose a significant decline in demand for viral-based editing technologies, as non-viral methods gained favor for their cost-effectiveness and efficiency [1]. - The truth about the company's situation was revealed on January 9, 2025, when Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27% [1]. Stock Price Impact - Following the announcement of the discontinuation of NTLA-3001, Intellia's stock price dropped from $12.02 per share on January 8, 2025, to $10.20 per share on January 10, 2025 [1]. Next Steps for Shareholders - Shareholders who purchased NTLA shares during the specified class period are encouraged to register for the class action by April 14, 2025, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [2]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to misleading statements or omissions by companies [3].

Core Viewpoint - Intellia Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 30, 2024, and January 8, 2025 [1][2] Group 1: Lawsuit Details - The lawsuit aims to recover losses for Intellia investors who were impacted by the company's failure to disclose critical information regarding its Phase 1/2 study of NTLA-3001 for treating alpha-1 antitrypsin deficiency (AATD)-associated lung disease [2] - Defendants allegedly misled investors by expressing confidence in the study's timeline, stating that the first patient would be dosed in the second half of 2024, while failing to reveal that demand for viral-based editing was declining in favor of non-viral methods [2] - On January 9, 2025, Intellia announced a reorganization, halting all NTLA-3001 research and reducing its workforce by 27%, leading to a significant drop in stock price from $12.02 on January 8, 2025, to $10.20 on January 10, 2025 [2] Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until April 14, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3] - Class members may be entitled to compensation without incurring out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the United States [4]

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Intellia To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $50,000 in Intellia between July 30, 2024 and January 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 20, 2025 /PRNewswire/ ...

CAMBRIDGE, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2024 financial results and operational highlights in a conference call on February 27, 2025, at 8 a.m. ET. To join the call: U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the cal ...

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc ("Intellia" or the "Company") (NASDAQ :NTLA).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Intellia and certain of it ...

NEW YORK, Feb. 18, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ: NTLA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Intellia investors who were adversely affected by alleged securities fraud between July 30, 2024 and January 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/intellia-therapeutics- ...

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 14, 2024.So what: If you purchased Intellia securities during the Clas ...